Find Academic Supervisors

Ilaria RussoView profile

Lecturer

• Malaria Research
• Infectious Diseases
• Host-Pathogen Interactions
• +3 more

Dr. Ilaria Russo is a Lecturer in Bioscience at the Keele University School of Medicine. Her roles combine teaching and research in medical microbiology, pharmacology, and infectious diseases. She leads research on Plasmodium cell biology, malaria pathogenesis, and antimalarial drug targets. She holds an honorary Adjunct Professorship at Washington University in St. Louis, USA. Education: MSc in Pharmaceutical Chemistry (University of Padua), PhD in Cellular and Molecular Biology (University of Padua). Postdoctoral training at Washington University, supported by NIH and ERC grants. She has pioneered studies on Plasmodium's secretory pathways and validated novel drug targets such as calpain and plasmepsin V. Research Interests: Host-pathogen interactions, malaria parasite biology, vaccine development, and innovative in vitro models (e.g., BBB models, organoids). Her work bridges lab discoveries with field applications in the Democratic Republic of Congo (DRC), including diagnostic initiatives via the Fonte di Speranza Foundation. Key Achievements: Discovery of calpain and plasmepsin V as antimalarial targets, development of conditional knockdown techniques, and leadership in global health projects. Awards: ERC Reintegration Grant, Wellcome Trust Fellowship, and editorial roles in journals like Enliven: Immunology . Labs/Teams: Part of Keele's Centre for Applied Entomology and Parasitology (CAEP), collaborating with global networks including the Goldberg Lab (Washington University).

• Developmental Biology
• Regenerative Medicine
• Cardiovascular Development
• +3 more

Mathilda Mommersteeg is an Associate Professor of Developmental and Regenerative Medicine at the University of Oxford's Department of Physiology, Anatomy & Genetics (DPAG), and Deputy Director of Graduate Studies at St Cross College. She holds a PhD from the University of Amsterdam (2009) and conducted postdoctoral research at University College London (UCL), supported by an EMBO fellowship. Her work focuses on understanding molecular mechanisms underlying heart regeneration and development, particularly using zebrafish and Mexican cavefish models. Key research areas include Slit-Robo signaling pathways, cardiac innervation, and the genetic basis of regenerative success. Her research has identified critical roles for genes like Lrrc10 and Runx1 in heart regeneration, and she has pioneered studies on population-specific differences in regenerative capacity between surface and cave-dwelling Mexican cavefish. Mommersteeg's contributions span developmental cardiology, regenerative biology, and comparative genomics, with a focus on translating findings to improve human cardiac repair strategies. Education: PhD in Developmental Biology, University of Amsterdam (2009) Labs/Groups: Mommersteeg Group (Oxford) Grants/Funding: Supported by the British Heart Foundation (BHF) and other initiatives Her recent work emphasizes the interplay between cardiomyocyte proliferation and fibrotic responses in regeneration failure, with studies revealing how genetic and environmental factors influence repair outcomes.

Marta ShahbaziView profile

Research Fellow

• Developmental Biology
• Stem Cell Biology
• Embryogenesis
• +4 more

Dr. Marta Shahbazi is an Affiliated Principal Investigator at the Cambridge Stem Cell Institute, University of Cambridge, and maintains a primary affiliation with the MRC Laboratory of Molecular Biology. She leads the Shahbazi Lab, which focuses on understanding the mechanisms that control pluripotent stem cell identity and fate in physiological 3D contexts. Her research bridges developmental biology and stem cell research, with particular emphasis on how tissue architecture influences stem cell behavior during embryonic development and potential regenerative applications. Dr. Shahbazi's research interests center around pluripotent stem cells and their role in early mammalian development. Her work investigates how pluripotent cells undergo concomitant changes in shape and identity to establish the foundation of the body plan. She is particularly interested in epithelial tissue determinants and their contribution to stem cell fate decisions. Her lab employs novel methods to culture mouse and human embryos, 3D embryonic stem cell models, and adult tissue organoids to understand the molecular pathways coordinating tissue shape and stem cell fate during pluripotency exit and acquisition. Analysis of Dr. Shahbazi's recent publications reveals a strong focus on human and mouse embryogenesis, with particular attention to tissue morphogenesis, cell delamination, and the molecular mechanisms underlying pluripotency transitions. Her work spans from basic developmental mechanisms to potential applications in regenerative medicine, with increasing emphasis on human embryo models in recent years. The research demonstrates interdisciplinary approaches combining cell biology, developmental biology, and tissue engineering principles. Dr. Shahbazi has received recognition through multiple publications in high-impact journals including Nature, Developmental Cell, and Cell Stem Cell. Her work on human embryo development and stem cell-based embryo models has contributed significantly to the field. Dr. Shahbazi mentors several researchers in her lab, including Viviane de Souza Rosa, Miguel Ángel Ortiz Salazar, Rina Sakata, Nanami Satoh, Luca Schwarz, and Anfu Wang. Her research is supported by the Cambridge Stem Cell Institute and the MRC Laboratory of Molecular Biology, providing resources for advanced imaging, genomics, and tissue culture facilities. The Shahbazi Lab is part of the broader Cambridge research ecosystem focused on stem cells and developmental biology, collaborating with other principal investigators at the Cambridge Stem Cell Institute.

Benedikt KesslerView profile

Professor

• Ubiquitin-Proteasome System
• Deubiquitylating Enzymes
• Proteomics
• +7 more

Professor Benedikt Kessler is a Full Professor of Biochemistry and Mass Spectrometry at the Target Discovery Institute within the Nuffield Department of Medicine at the University of Oxford. He leads a research group focused on the ubiquitin-proteasome system and deubiquitylating enzymes, with significant contributions to cancer research and neurodegenerative disease therapeutics. Professor Kessler received his B.A. in Biochemistry from the Swiss Federal Institute of Technology in 1992, followed by a Ph.D. in Immunology from the Ludwig Institute for Cancer Research. He completed post-doctoral training at Harvard Medical School under Hidde Ploegh before joining the University of Oxford in 2004 as a Research Group Leader. He established his independent research group in 2005 and relocated to the Target Discovery Institute in 2013. In 2014, he was promoted to Full Professor of Biochemistry & Life Science Mass Spectrometry. His research focuses on deubiquitylating enzymes (DUBs) and their role in cellular processes, with particular emphasis on cancer development and neurodegenerative disorders. Professor Kessler pioneered chemoproteomics methods to profile active ubiquitin processing enzymes and has made significant contributions to understanding how ubiquitin-based pathways can be targeted therapeutically. His laboratory developed ubiquitin-based active site directed probes that enabled profiling of active cellular DUB content, leading to discoveries about OTUB1 in infection and prostate cancer, USP4 and USP47 in DNA repair, and USP18 in immuno-oncology. His work has directly contributed to the development of novel inhibitors for DUBs including USP30 (for Parkinson's disease), USP28 (for squamous lung carcinoma), and USP7 (for multiple myeloma). Analysis of Professor Kessler's recent publications (2024-2025) reveals an expanding research portfolio with significant contributions across multiple domains: neurodegenerative disease therapeutics through hydrogen deuterium exchange mass spectrometry, kidney transplant immunology, ubiquitin pathway characterization in infectious diseases like malaria, and novel DUB inhibitor development. His work consistently bridges fundamental biochemistry with clinical applications, particularly in cancer therapeutics and neurodegenerative disorders, while increasingly incorporating advanced machine learning approaches for biomarker discovery. Scientific Awards and Recognition Cesar Roux Research Award of the Faculty of Medicine, Lausanne University Human Frontier Science Program Organization long-term fellowship Roche Research Foundation post-doctoral fellowship Multiple Myeloma Research Foundation Senior Research Award Wellcome Trust VIP Award (2005) MRC New Investigator Award (2006-2009) Professor Kessler's research has received substantial funding throughout his career, including the MRC New Investigator Award that supported his early independent work at Oxford. His contributions to understanding the ubiquitin-proteasome system led to translational applications, most notably contributing to the development of Velcade™ for multiple myeloma treatment. He is an active member of several prestigious scientific organizations including the British Mass Spectrometry Society, British Society of Cell Biology, and the American Association for Cancer Research. Professor Kessler serves as a NIH study section member and collaborates extensively through the DUB Alliance and Pfizer's Innovative Technology Enabling Network (ITEN). Professor Kessler leads the TDI Mass Spectrometry Laboratory at the Nuffield Department of Medicine, where his team develops advanced chemoproteomics methods to profile active ubiquitin processing enzymes. His laboratory maintains extensive collaborations across Oxford University including with the Oxford Ludwig Institute, Jenner Institute, Weatherall Institute of Molecular Medicine, and Structural Genomics Consortium. Internationally, he collaborates with researchers at Leiden University and maintains connections with the Harvard Medical School community where he began his academic career.

• Cancer Metabolism
• Oncology
• LC-MS Metabolomics
• +7 more

Dr. Victor H Villar is a Research Fellow at the School of Medicine, University of St Andrews. He is affiliated with the Sir James Mackenzie Institute for Early Diagnosis and Cellular Medicine Division. His work focuses on cancer metabolism, biomarker discovery, and therapeutic strategies. Metabolism and Biomarkers Lab LC-MS-based metabolomics research His research interests include: Hepatocellular Carcinoma Soft Tissue Sarcoma Esophageal Cancer Tumor metabolism Cell signaling Autophagy Recent publications reveal trends in: Metastasis mechanisms Lipid metabolism in cancer Immunotherapy targets Metabolic pathway analysis Stromal-tumor interactions Physiological cell culture models Dr. Villar supervises postgraduate research students Mark Kelly and Keira Hughes, who are investigating biomarker discovery for hepatocellular carcinoma and sarcoma subtypes, respectively. The Metabolism and Biomarkers Lab employs LC-MS metabolomics to identify metabolic alterations in cancers.

Patrick KennedyView profile

Clinical Professor

• Viral Hepatitis
• Translational Hepatology
• Immunology
• +9 more

Professor Patrick Kennedy is a Clinical Professor of Translational Hepatology at the Faculty of Medicine and Dentistry , Queen Mary University of London (QMUL), and a Consultant Hepatologist at Barts Health NHS Trust. His research focuses on the translational aspects of Hepatitis B virus (HBV) infection, particularly in young adults, and he leads the dedicated young adult liver service at The Royal London Hospital. Research Themes : Redefining disease phases in Chronic Hepatitis B (CHB), age-related immune responses, treatment endpoints in CHB, and immune-mediated liver injury mechanisms. Collaborations : Works with national institutions like UCL, Imperial College London, and international partners such as Duke-NUS Medical School (Singapore) and University of Rome Tor Vergata (Italy). Teaching : Chairs the MSc in Gastroenterology program and contributes to undergraduate MBBS teaching, including bedside clinical instruction and virology modules.

Simon MoxonView profile

Associate Professor

• Bioinformatics
• Gene Regulation
• Next-Generation Sequencing
• +3 more

Simon Moxon is an Associate Professor in Bioinformatics at the University of East Anglia (UEA), part of the School of Biological Sciences. His research focuses on applying next-generation sequencing (NGS) technologies to study biological problems, particularly small RNA bioinformatics and mechanisms of gene regulation at transcriptional and post-transcriptional levels. He has developed tools like miRCat2 and the UEA sRNA Workbench for miRNA detection and analysis. Notable collaborations include projects funded by the British Heart Foundation, NIH, and the Natural Environment Research Council, exploring topics such as chromatin landscapes, microRNA biogenesis, and epigenetic reprogramming. His work spans plant genomics, developmental biology, and molecular mechanisms in diseases like cancer. Recent publications highlight advancements in understanding miRNA regulation in plants and animals, epigenetic marks during zygotic reprogramming, and antimicrobial resistance in Bacillus species. Moxon actively mentors PhD students and contributes to editorial roles in journals like Frontiers in Molecular Biosciences.

Delvac OceandyView profile

Professor

• Cardiac Regeneration
• Hippo Signaling Pathway
• Cardiac Hypertrophy
• +3 more

Delvac Oceandy is a Professor of Molecular Cardiovascular Sciences at the University of Manchester, affiliated with the Division of Cardiovascular Sciences (L5). He holds an adjunct professorship at Universitas Airlangga, Indonesia. His research focuses on molecular mechanisms of cardiac regeneration, Hippo signaling pathways, and calcium signaling in cardiovascular diseases. He has led multiple grants from the British Heart Foundation (BHF), Medical Research Council (MRC), and Heart Research UK, totaling over £2.5 million in funding since 2010. Dr. Oceandy's teaching portfolio includes undergraduate medical (MBChB) and biomedical sciences (BSc) programs, as well as postgraduate MSc programs in Cardiovascular Health and Tissue Engineering. He supervises PhD students and serves on editorial boards for journals like Nature Scientific Reports. His laboratory employs advanced techniques in molecular biology, cell biology, and translational medicine to address heart failure and regeneration challenges. Key achievements include the 2006 ESC Young Investigator Award and 2010 BHF Intermediate Fellowship. Current research projects target Hippo pathway modulation, PMCA4 inhibition in myocardial infarction, and microRNA-based therapies for cardiac dysfunction. He collaborates widely, with recent work on mobile health interventions in rural Indonesia to reduce cardiovascular mortality.

Cressida LyonView profile

Senior Lecturer

• Cardiovascular Science
• Vascular Biology
• Atherosclerosis
• +11 more

Cressida Lyon is a Senior Lecturer in the Department of Life Sciences within the Faculty of Science at the University of Bath. She serves as Director of Studies for the Biomedical Sciences programmes and is actively engaged in pedagogic research and biosciences education. Her academic journey began with a PhD in Cardiovascular Science from the University of Bristol, followed by over a decade of post-doctoral research at the same institution. Education: PhD in Cardiovascular Science, University of Bristol (2003–2006) BSc in Biochemistry, Imperial College London (2000–2003) Her research expertise spans both cardiovascular biology and educational innovation. Early research focused on the role of N-cadherin in vascular smooth muscle cells and atherosclerosis. Currently, her pedagogic research emphasizes active engagement with feedback through ePortfolio systems, Team Based Learning , and enhancing inclusivity in biosciences education . She supervises undergraduate research projects and provides personal tutoring. The recent publication trend reflects a shift from vascular biology to educational scholarship, with her most recent contribution being an editorial on cellular reprogramming in 2023. Earlier works (2011–2017) centered on molecular mechanisms of vascular disease, particularly targeting N-cadherin pathways for therapeutic intervention in atherosclerosis and aneurysm. Scientific Awards: Senior Fellowship of the Higher Education Academy (2024) Fellowship of the Higher Education Academy (2020) She has held external roles including Senior Research Associate and Research Associate at the University of Bristol, and a Programme Manager position at the Biotechnology and Biological Sciences Research Council (BBSRC). While no formal advisees are listed, she mentors undergraduate students through research projects and personal tutoring. There is no mention of specific research labs or collaborative teams in the provided text.

Tatiana NovoselovaView profile

Lecturer

• Neurodegenerative disorders
• Ataxias
• Metabolic regulation
• +4 more

Dr. Tatiana Novoselova serves as a Lecturer in Medical Sciences at the Institute of Health Sciences Education (IHSE) within Queen Mary University of London's Faculty of Medicine and Dentistry. She co-leads the Metabolism module for Phase 1 of the MBBS program and acts as Senior Internal Examiner for Year 2 Paper B, while teaching Metabolism and Brain and Behaviour modules across Year 1-2 MBBS and Graduate Entry Programme cohorts. Her educational background includes an MBBS from a top Russian medical school, followed by a PhD in Molecular and Cellular Neuroscience at University College London. This foundation supports her dual expertise in clinical education and laboratory research. Novoselova's research centers on molecular mechanisms of neurodegenerative disorders and ataxias, with significant contributions to understanding central metabolic regulation, obesity pathophysiology, and adrenal gland physiology. Her work bridges neuroscience and endocrinology through investigations of melanocortin receptor signaling, mitochondrial dysfunction in optic atrophy, and adrenal zonation defects. Analysis of her 15 most recent publications (2013-2022) reveals a consistent focus on genetic and molecular underpinnings of disease, utilizing iPSC models, multi-omic profiling, and animal studies. Key thematic clusters include optic atrophy mechanisms (OPA1-related), adrenal insufficiency genetics (MRAP/NNT pathways), and obesity-related neural circuits (melanocortin systems), demonstrating translational approaches from basic science to therapeutic strategies. No scientific awards, prizes, fellowships, or medals were documented in the source material. During her tenure at Middlesex University London, Novoselova supervised MSc and PhD students while leading the MSc Computational Neuroscience program. Current advising roles at Queen Mary include Senior Tutor and Academic Adviser for MBBS students, though specific grant funding details remain unreported. Her academic leadership extends to REF2021 contributions and ethics committee service. While collaborative research networks are evident through co-authored publications on adrenal physiology and neurodegeneration, explicit laboratory affiliations or dedicated research teams at Queen Mary were not specified in the available documentation.

• Cancer Metabolism
• Mitochondrial Biology
• Leukemia Research
• +3 more

Dr. David Sumpton serves as an Honorary Senior Lecturer within the School of Cancer Sciences at the University of Glasgow, affiliated with the CRUK Scotland Institute in Glasgow. His research bridges cancer biology, metabolism, and therapeutic development, with particular focus on mitochondrial function in malignancies. His research interests center on cancer metabolism , especially mitochondrial pathways driving tumor progression and metastasis. Key areas include nucleotide metabolism (uridine phosphorylase), folate cycle regulation in leukemia, lipid signaling in metastatic niches, and immunometabolism interactions. His work demonstrates how metabolic rewiring enables immune evasion, metastatic colonization, and therapeutic resistance across prostate cancer, leukemia, and solid tumors. Analysis of his 2023-2025 publications reveals strong emphasis on metabolic vulnerabilities for therapeutic targeting, including drug repurposing (lomerizine for CML), mitochondrial DNA mutations enhancing immunotherapy response, and nutrient transporter dependencies (SLC7A5). His team frequently employs multi-omics approaches to stratify cancer subtypes and identify biomarker-driven treatments. While no formal advising or grant information is publicly documented, his collaborative publications across Nature journals, Science Translational Medicine, and Cell Biology indicate extensive institutional partnerships. His lab appears focused on translating metabolic discoveries into preclinical therapeutic strategies, particularly for treatment-resistant cancers. Dr. Sumpton maintains active research in tumor microenvironment dynamics, with recent work on extracellular vesicle-mediated metastatic niche formation and senescence-induced multi-organ dysfunction. His team utilizes physiological cell culture models to improve metabolic fidelity in cancer research.

Tony PerryView profile

Professor

• Embryology
• Developmental Biology
• Gamete-to-Embryo Transition
• +13 more

Tony Perry is a Professor in the Department of Life Sciences at the University of Bath, where he leads pioneering research in mammalian embryogenesis and the gamete-to-embryo transition. He is actively accepting doctoral students and has been principal investigator on multiple research projects funded by the MRC and BBSRC. His lab integrates embryological, molecular, and imaging techniques to study totipotency, epigenetic reprogramming, and genome editing in mouse models. Research Interests: Embryology and developmental biology Mechanisms of cellular potency and totipotency Epigenetic reprogramming during fertilization Genome editing and transgenesis Nuclear transfer and cloning technologies Applications in infertility and regenerative medicine His recent publications demonstrate groundbreaking work in reprogramming pathways, mechanical forces in early embryos, and switchable gene editing. These studies span disciplines including developmental biology, molecular genetics, and nanobiology, with strong translational implications for assisted reproductive technologies and mitochondrial disease prevention. Scientific Recognition: Work featured in over 96 news outlets Publications widely shared on social media (X, Facebook) Referenced in patents and academic platforms like Mendeley and CiteULike Active conference participation Advising and Grants: Professor Perry supervises doctoral researchers and leads multiple funded projects, including New Perspectives on Imprinting Disease (MRC, 2022–2026) and Switchable Gene Drives (BBSRC, 2017–2021). His research is supported by major UK funding councils and involves interdisciplinary collaboration across biochemistry, genetics, and biomedical engineering. He also contributes to collaborative platforms such as high-throughput peptide synthesis. Labs and Teams: His research group at the University of Bath operates at the intersection of embryology and molecular innovation, utilizing advanced tools like piezo-actuated micromanipulation and sub-cellular transcriptomics. The team includes researchers like Masashi Asami and collaborates internationally. The lab’s website ( egg2embryo.com ) highlights their mission and key discoveries, including England’s first cloned mouse from an adult cell.

Sevasti ZervouView profile

Lecturer

• Cellular Biochemistry
• Metabolism
• Genetics
• +5 more

Dr Sevasti Zervou is a Stipendiary Lecturer in Cellular Biochemistry at St Peter’s College, University of Oxford, and Director of Studies for the MSc Precision Cancer Medicine program in the Department of Oncology. She holds a PhD in Molecular Medicine from the University of Warwick (2001) and has over 15 years of research experience in cardiovascular medicine, funded by the British Heart Foundation. Her academic roles include teaching undergraduate biochemistry, leading postgraduate modules in genetics for precision oncology, and mentoring junior researchers. Her research focuses on cellular metabolism, genetic regulation of heart function, and metabolic pathways in cardiovascular diseases, diabetes, and cancer. She has pioneered studies on creatine kinase systems, myocardial energetics, and therapeutic targets for heart failure. Beyond academia, she contributes to science outreach through guest lectures for sixth-form students and mentorship programs. Education: BSc (Hons) in Molecular Medicine (Warwick), PhD (Warwick), FHEA (Fellow of the Higher Education Academy). Research expertise includes molecular cloning, transcriptomics, proteomics, and high-throughput drug screening. She coordinates the MSc Precision Cancer Medicine program, overseeing academic content and teaching delivery. Her work integrates clinical research with educational innovation, emphasizing translational applications of cellular biochemistry. Her research portfolio includes over 30 peer-reviewed publications on topics like cardiac energetics, creatine metabolism, and nanomaterials for cardiovascular therapy. She collaborates with multidisciplinary teams in Oxford and has contributed to understanding metabolic inflexibility in heart disease. Teaching responsibilities span undergraduate tutorials in biochemistry (cell structure, metabolism, data analysis) and postgraduate modules in genetic oncology. She actively participates in academic governance as a Member of Congregation at St Peter’s College.

Owen SansomView profile

Professor

• Colorectal Cancer
• Wnt Signalling
• Cancer Biology
• +6 more

Professor Owen Sansom is Director of the Cancer Research UK Scotland Institute in Glasgow, where he leads the Colorectal Cancer and Wnt Signalling research group. His work focuses on understanding the molecular mechanisms underlying colorectal cancer initiation, progression, and metastasis using state-of-the-art preclinical models. His educational background includes a PhD from the University of Edinburgh (2002), MRes in Biology from the University of Manchester (1997), and BSc in Genetics (First Class Honours) from the University of Nottingham (1996). Prior to his current role as Director (since 2017), he served as Deputy Director of the CRUK Beatson Institute (2011-2017) and has been a Group Leader at the institute since 2005. Professor Sansom's research interests center on colorectal cancer biology, particularly Wnt signaling pathways, cancer stem cells, and therapeutic resistance mechanisms. His lab utilizes genetically engineered mouse models to investigate how key driver mutations contribute to cancer development and response to therapy. He is particularly interested in developing stage- and subtype-specific targeted therapies for colorectal cancer patients. His recent publications reveal significant trends in colorectal cancer research, with strong emphasis on cellular plasticity, tumor heterogeneity, metabolic reprogramming, and the tumor microenvironment. His work spans molecular mechanisms, preclinical models, and translational applications, with particular focus on WNT-dependent colorectal cancer, therapeutic vulnerabilities, and metastasis mechanisms. Fellow of the Academy of Medical Sciences (2017) CRUK Future Leaders in Cancer Research Prize (2012) Fellow of the Royal Society of Edinburgh (2012) BACR/AstraZeneca Young Scientist Frank Rose Award (2007) Professor Sansom actively mentors numerous PhD students and postdoctoral researchers in his lab, supervising projects related to colorectal cancer biology, metastasis, and therapeutic resistance. His research is supported by multiple funding sources including Cancer Research UK, industry partnerships with Novartis, and participation in major cancer consortia such as ACRCelerate, CRUK Grand Challenge Rosetta, and CRUK Grand Challenge SpecifiCancer. His lab operates as part of the Cancer Research UK Scotland Institute, where they utilize advanced preclinical models, organoid culture systems, and multi-omics approaches to investigate colorectal cancer biology. The team includes bioinformaticians, postdoctoral scientists, clinical research fellows, and graduate students working collaboratively on various aspects of colorectal cancer research.

Jennifer DewingView profile

Research Fellow

• Neurodegenerative Diseases
• Stem Cell Modeling
• TIMP-3 Proteinopathy
• +3 more

Dr Jennifer Dewing is a Research Fellow in Clinical Neuroanatomy at the University of Southampton. Her work focuses on neurodegenerative diseases, particularly investigating TIMP-3 proteinopathy mechanisms and retinal/brain degeneration. She has contributed to studies on fetal heart development, autism-related synaptic dysfunction, and stem cell models of Sorsby Fundus Dystrophy. Her research bridges molecular biology, clinical pathology, and developmental biology. Notable awards include the British Neuropathological Society's best oral presentation (2025) and recognition for her TIMP-3 proteinopathy work (2023). Dr Dewing collaborates across disciplines, with publications in high-impact journals like PLoS ONE and The Journal of Pathology. Her current projects include exploring age-associated neurodegenerative mechanisms and cardiac cell composition in early fetal development.